Compare SPRO & QXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | QXL |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.0M | 75.6M |
| IPO Year | 2017 | 2015 |
| Metric | SPRO | QXL |
|---|---|---|
| Price | $1.10 | $4.41 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 839.8K | 57.2K |
| Earning Date | 11-12-2026 | 08-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | N/A | ★ 0.10 |
| Revenue | ★ $66,802,000.00 | $26,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $38.79 |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $1.08 | $3.70 |
| 52 Week High | $3.08 | $7.70 |
| Indicator | SPRO | QXL |
|---|---|---|
| Relative Strength Index (RSI) | 41.51 | 45.43 |
| Support Level | $1.10 | $4.13 |
| Resistance Level | $1.28 | $5.18 |
| Average True Range (ATR) | 0.06 | 0.40 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 2.50 | 36.88 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Quantum X Labs Inc is an Israel-based multi-disciplinary quantum technology company focused on the research, development, and commercialization of quantum technologies and intellectual property. The company operates across a broad range of domains, including quantum computing, quantum sensing, navigation systems, atomic clocks, and quantum algorithms, with applications spanning defense, aerospace, transportation, cybersecurity, and life sciences.